Anifrolumab serum PK parameters following subcutaneous and intravenous administration of anifrolumab
| Anifrolumab | |||
| 300 mg SC (n=6) | 300 mg IV (n=6) | 600 mg SC (n=6)* | |
| AUC (day·μg/mL), mean (SD) | 785 (331) | 907 (175) | 1828 (680) |
| Cmax (μg/mL), mean (SD) | 36.2 (11.6) | 82.4 (13.2) | 63.9 (20.5) |
| tmax (day), median (range) | 4.1 (4.0–7.0) | 0.03 (0.03–1.03) | 7.0 (4.0–9.0) |
| CL (L/day), mean (SD) | NA | 0.34 (0.05) | NA |
| CL/F (L/day), mean (SD) | 0.43 (0.17) | NA | 0.37 (0.16) |
*N=5 for AUC and CL/F because one individual was lost to follow-up after Day 22.
AUC, area under the serum concentration-time curve from time 0 extrapolated to infinity; Cmax, maximum serum concentration; CL, total body clearance after intravenous administration; CL/F, apparent total body clearance after extravascular administration estimated as dose divided by AUC; IV, intravenous; NA, not applicable; SC, subcutaneous; tmax, time to reach maximum serum concentration.